Edwards Lifesciences Corp (NYSE:EW) Holdings Raised by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. boosted its stake in Edwards Lifesciences Corp (NYSE:EW) by 11.9% in the first quarter, Holdings Channel reports. The institutional investor owned 29,780 shares of the medical research company’s stock after acquiring an additional 3,172 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Edwards Lifesciences were worth $5,617,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. National Asset Management Inc. lifted its position in Edwards Lifesciences by 94.2% in the 4th quarter. National Asset Management Inc. now owns 2,159 shares of the medical research company’s stock worth $505,000 after buying an additional 1,047 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Edwards Lifesciences by 1.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 164,152 shares of the medical research company’s stock valued at $38,295,000 after purchasing an additional 2,104 shares in the last quarter. First American Bank bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at $12,690,000. NEXT Financial Group Inc raised its holdings in shares of Edwards Lifesciences by 68.6% during the 4th quarter. NEXT Financial Group Inc now owns 1,116 shares of the medical research company’s stock valued at $260,000 after purchasing an additional 454 shares in the last quarter. Finally, Carderock Capital Management Inc. bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at $1,317,000. Institutional investors own 81.22% of the company’s stock.

In related news, VP Larry L. Wood sold 3,566 shares of Edwards Lifesciences stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $207.00, for a total transaction of $738,162.00. Following the completion of the transaction, the vice president now directly owns 120,995 shares of the company’s stock, valued at approximately $25,045,965. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jean-Luc M. Lemercier sold 3,470 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $217.53, for a total transaction of $754,829.10. Following the transaction, the vice president now directly owns 45,288 shares of the company’s stock, valued at $9,851,498.64. The disclosure for this sale can be found here. Insiders have sold a total of 95,878 shares of company stock valued at $20,047,408 over the last three months. 1.48% of the stock is currently owned by insiders.

A number of research firms recently issued reports on EW. Zacks Investment Research upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $231.00 target price on the stock in a research note on Monday, February 3rd. Canaccord Genuity reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, April 24th. Morgan Stanley raised their target price on shares of Edwards Lifesciences from $241.00 to $250.00 and gave the company an “overweight” rating in a research note on Friday, April 24th. Deutsche Bank lowered their target price on shares of Edwards Lifesciences from $245.00 to $225.00 and set a “hold” rating on the stock in a research note on Wednesday, April 22nd. Finally, Citigroup raised their target price on shares of Edwards Lifesciences from $240.00 to $255.00 and gave the company a “buy” rating in a research note on Friday, April 24th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and sixteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $247.52.

Shares of Edwards Lifesciences stock opened at $218.81 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.47 and a current ratio of 3.36. The firm’s 50-day simple moving average is $212.94 and its 200-day simple moving average is $222.43. Edwards Lifesciences Corp has a twelve month low of $154.52 and a twelve month high of $247.64. The firm has a market cap of $45.13 billion, a P/E ratio of 41.84, a price-to-earnings-growth ratio of 2.75 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $1.51 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.22. Edwards Lifesciences had a net margin of 24.71% and a return on equity of 31.83%. The business had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same period in the previous year, the business earned $1.32 EPS. The firm’s revenue was up 13.7% on a year-over-year basis. On average, equities analysts forecast that Edwards Lifesciences Corp will post 4.95 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Story: What is a dead cat bounce?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.